FDA approves combination immunotherapy treatment for metastatic kidney cancer
The Food and Drug Administration grants approval for the combination of two immunotherapy drugs, ipilimumab and nivolumab, for the treatment of metastatic kidney cancer. The approval comes following the findings of the CheckMate-214 study, which was sponsored by Bristol-Myers Squibb and co-led by Dr. Hans Hammers. Press Release
Dr. Hannan and colleagues report on efficacy of immune checkpoint inhibition combined with SBRT
Dr. Raquibul Hannan and colleagues report results from one of the largest series of cancer patients (mostly kidney and melanoma) treated with immune checkpoint inhibitors together with modern hypofractionated radiation, such as stereotactic body radiation therapy (SBRT). Abstract
Former kidney donor joins KCP staff as first Director of Patient Experience at UT Southwestern
The KCP welcomes Megan Dougherty, R.N., as Director of Patient Experience. Ms. Dougherty will be the first Director of Patient Experience at UT Southwestern.
KCP holds the 2nd Annual Rock the Cure event
KCP Community gathers at the Dallas Country Club for a fun fundraising event organized by patient advocate Merlinda Chelette.
Dr. Brugarolas speaks at the UTSW President's Advisory Board meeting
Along with Dr. Arteaga (Director of Simmons Comprehensive Cancer Center) and Dr. Choy (Chairman of Radiation Oncology), Dr. Brugarolas addresses the President's Advisory Board at their yearly meeting on the healthcare mission of the academic medical center.
Dr. Brugarolas awarded two CPRIT grants
Dr. Brugarolas receives two Individual Investigator Research Award grants from CPRIT totaling over $2 million - a renewal grant investigating the implications of BAP1 and PBRM1 loss in renal cancer, and a second grant, which focuses on a rare, but devastating form of renal cancer, translocation RCC. Press Release
State-of-the-art MRI technology bypasses need for biopsy
Featured on the cover of the Journal of Urology, Drs. Pedrosa, Cadeddu, and colleagues report a new multiparametric MRI approach with high sensitivity and specificity for the detection of clear cell renal cell carcinoma, which may reduce the need for biopsies. Press Release • Video
HIF-2 inhibitor effective against kidney cancer
The results of a Phase I clinical trial using a first-in-class HIF-2alpha inhibitor called PT2385 are reported in the Journal of Clinical Oncology. The drug, developed by Peloton Therapeutics, showed activity in highly pretreated patients and minimal side-effects. KCP researcher, Dr. Kevin Courtney, was the UTSW site PI and corresponding author of the report. Press Release
KCP hosts first retreat for trainees
The KCP hosted a retreat for trainees (medical students, interns, residents, fellows...) to discuss trainee projects, research opportunities, resources, and funding opportunities. Two $1,000 awards for best research projects were given - one to a student, Daniel Li (MS2), and one to a physician, Ali Pirasteh, M.D. (Assistant Instructor).